Protective effect of antirheumatic drugs on dementia in rheumatoid arthritis patients
Christopher J Edwards(University Hospital Southampton NHS Foundation Trust), Simon Lovestone(Royal Buckinghamshire Hospital), César Garriga(Instituto de Salud Carlos III), Daniel Prieto‐Alhambra(Nuffield Orthopaedic Centre), Nigel Arden(Nuffield Orthopaedic Centre), Cyrus Cooper(University Hospital Southampton NHS Foundation Trust)
Alzheimer s & Dementia Translational Research & Clinical Interventions
November 1, 2017
Cited by 79
Related Papers
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease
|Nature Genetics|2009|3.4k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
|Annals of the Rheumatic Diseases|2020|2.8k
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease
|Nature Genetics|2011|2.1k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
|Annals of the Rheumatic Diseases|2022|1.9k
SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe
|European Heart Journal|2021|1.7k